RE:RE:pp for 3000 test a dayBucky86 wrote: Regardless of what the long investors here will tell you this quarter 3 is make-or-break for this company. Not literally but practically for me. If they can't show real solid revenue and really be transparent about what's going on based on hard facts and results and personally I am likely out I'll give it to the end of 2020 to decide.
We had $1 million six weeks in to the quarter so the second six weeks surely garnered at least another million for a minimum of $2 million +. You're right though - we need to see it in black and white and will then know that Q4 will be double minimum from that. The Aristotle carrot is the big wildcard here as cancer detection ramps up - I for one want to see that the Gene Expression Assay testing is indeed covered by large health insurers - we saw last week that Blue Cross Arizona for example does not. I fired a question to Rebecca as did Frewill but no response yet.
If the Q numbers are what we expect and Aristotle has success, then we will be sitting pretty shortly.